Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1960 1
1961 3
1962 1
1963 3
1964 2
1965 9
1966 2
1967 1
1968 2
1970 1
1971 4
1973 1
1974 2
1975 2
1976 1
1977 11
1978 5
1979 11
1980 7
1981 6
1982 19
1983 7
1984 22
1985 14
1986 14
1987 9
1988 12
1989 11
1990 7
1991 5
1992 9
1993 6
1994 4
1995 7
1996 6
1997 9
1998 12
1999 3
2000 9
2001 9
2002 6
2003 7
2004 3
2005 4
2006 4
2007 6
2008 8
2009 12
2010 15
2011 9
2012 7
2013 7
2014 5
2015 4
2016 8
2017 1
2018 3
2019 8
2020 18
2021 11
2022 8
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Randomized Trial of Thymectomy in Myasthenia Gravis.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Wolfe GI, et al. N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. N Engl J Med. 2016. PMID: 27509100 Free PMC article. Clinical Trial.
Corrigendum.
Maria Forte I, Indovina P, Costa A, Antonella Iannuzzi C, Costanzo L, Marfella A, Montagnaro S, Botti G, Bucci E, Giordano A. Maria Forte I, et al. Among authors: bucci e. J Cell Physiol. 2020 Jul;235(7-8):5860-5861. doi: 10.1002/jcp.29621. Epub 2020 Feb 11. J Cell Physiol. 2020. PMID: 32249427 No abstract available.
Coronaviruses: Facts, Myths, and Hypotheses.
Carbone M, Green JB, Bucci EM, Lednicky JA. Carbone M, et al. Among authors: bucci em. J Thorac Oncol. 2020 May;15(5):675-678. doi: 10.1016/j.jtho.2020.02.024. Epub 2020 Mar 7. J Thorac Oncol. 2020. PMID: 32151778 Free PMC article. No abstract available.
On zombie papers.
Bucci EM. Bucci EM. Cell Death Dis. 2019 Feb 25;10(3):189. doi: 10.1038/s41419-019-1450-3. Cell Death Dis. 2019. PMID: 30804342 Free PMC article. No abstract available.
COVID-19 infection: the perspectives on immune responses.
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G. Shi Y, et al. Among authors: bucci e. Cell Death Differ. 2020 May;27(5):1451-1454. doi: 10.1038/s41418-020-0530-3. Epub 2020 Mar 23. Cell Death Differ. 2020. PMID: 32205856 Free PMC article. No abstract available.
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection.
Allegretti M, Cesta MC, Zippoli M, Beccari A, Talarico C, Mantelli F, Bucci EM, Scorzolini L, Nicastri E. Allegretti M, et al. Among authors: bucci em. Cell Death Differ. 2022 Jan;29(1):156-166. doi: 10.1038/s41418-021-00844-6. Epub 2021 Aug 17. Cell Death Differ. 2022. PMID: 34404919 Free PMC article. Review.
Look for methods, not conclusions.
Bassi R, Bucci EM, Calogero RA, Carninci P, Ciliberto G, Conte P, De Luca M, Corbellini G, Giordano A, Marchionni L, Massaro Giordano G, Parini A, Sbardella G. Bassi R, et al. Among authors: bucci em. Cell Death Dis. 2019 Dec 5;10(12):931. doi: 10.1038/s41419-019-2179-8. Cell Death Dis. 2019. PMID: 31804462 Free PMC article. No abstract available.
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Wolfe GI, et al. Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25. Lancet Neurol. 2019. PMID: 30692052 Free PMC article. Clinical Trial.
412 results